Edison Investment Research is suspending coverage on Probiodrug (PBD). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
20 Jan 2019
Probiodrug - Suspension of coverage
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Probiodrug - Suspension of coverage
Edison Investment Research is suspending coverage on Probiodrug (PBD). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.